{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:52:59Z","timestamp":1794455579970,"version":"4.9.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.autrev.2021.102831","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T03:40:45Z","timestamp":1618803645000},"page":"102831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Human mesenchymal stem cells for the management of systemic sclerosis. Systematic review"],"prefix":"10.1016","volume":"20","author":[{"given":"Carlos-Hugo","family":"Escobar-Soto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Mejia-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Alzate-Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mendoza-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Mungu\u00eda-Realpozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socorro","family":"M\u00e9ndez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Garc\u00eda-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rojas-Villarraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2021.102831_bb0005","first-page":"208","article-title":"Scleroderma with an update about clinico-pathological correlation","volume":"153","author":"Rongioletti","year":"2018","journal-title":"G Ital Di Dermatologia e Venereol"},{"key":"10.1016\/j.autrev.2021.102831_bb0010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.autrev.2016.01.007","article-title":"Systemic sclerosis: an update in 2016","volume":"15","author":"Desbois","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0015","doi-asserted-by":"crossref","first-page":"102396","DOI":"10.1016\/j.autrev.2019.102396","article-title":"Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy","volume":"18","author":"Henry","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0020","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2017.05.024","article-title":"The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review","volume":"16","author":"Mostmans","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0025","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102831_bb0030","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.autrev.2021.102831_bb0035","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/1756-185X.13716","article-title":"Prevalence and incidence of systemic sclerosis: a systematic review and meta-analysis","volume":"22","author":"Zhong","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102831_bb0040","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.berh.2018.08.005","article-title":"Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis","volume":"32","author":"Ingegnoli","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102831_bb0045","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102831_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: systematic review and meta-analysis","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102831_bb0055","doi-asserted-by":"crossref","first-page":"102394","DOI":"10.1016\/j.autrev.2019.102394","article-title":"Fast track algorithm: How to differentiate a \u201cscleroderma pattern\u201d from a \u201cnon-scleroderma pattern\u201d","volume":"18","author":"Smith","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0060","doi-asserted-by":"crossref","first-page":"102449","DOI":"10.1016\/j.autrev.2019.102449","article-title":"Thermography in systemic sclerosis patients and other rheumatic diseases: diagnosis, disease activity assessment, and therapeutic monitoring","volume":"19","author":"Sciascia","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.autrev.2018.09.002","article-title":"Nailfold avascular score and coronary microvascular dysfunction in systemic sclerosis: a newsworthy association","volume":"18","author":"Zanatta","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0070","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.autrev.2018.03.012","article-title":"Therapy of scleroderma renal crisis: state of the art","volume":"17","author":"Zanatta","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0075","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102831_bb0080","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001728","article-title":"Registry of the Spanish network for systemic sclerosis","volume":"94","author":"Sime\u00f3n-Aznar","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2021.102831_bb0085","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.autrev.2018.10.006","article-title":"Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: a case series and systematic review of the literature","volume":"18","author":"Narv\u00e1ez","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0090","doi-asserted-by":"crossref","first-page":"102403","DOI":"10.1016\/j.autrev.2019.102403","article-title":"Is there today a place for corticosteroids in the treatment of scleroderma?","volume":"18","author":"Blagojevic","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0095","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.autrev.2017.07.018","article-title":"How I treat patients with systemic sclerosis in clinical practice","volume":"16","author":"Rossi","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0100","doi-asserted-by":"crossref","first-page":"102409","DOI":"10.1016\/j.autrev.2019.102409","article-title":"Cannabinoids in the treatment of rheumatic diseases: pros and cons","volume":"18","author":"Sarzi-Puttini","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2008.03.002","article-title":"Mesenchymal stem cells: revisiting history, concepts, and assays","author":"Bianco","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.autrev.2021.102831_bb0110","article-title":"NN Mesenchymal stem cells reside in virtually all post-natal organs and tissues","author":"da Silva Meirelles","year":"2006","journal-title":"J Cell Sci"},{"key":"10.1016\/j.autrev.2021.102831_bb0115","doi-asserted-by":"crossref","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"10.1016\/j.autrev.2021.102831_bb0120","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3390\/cells8080886","article-title":"Mesenchymal stem cells for regenerative medicine","volume":"8","author":"Han","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2021.102831_bb0125","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1089\/scd.2015.0008","article-title":"PageMesenchymal stem cells therapy for autoimmune disease: risks and rewards","volume":"24","author":"Hafsa","year":"2015","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.autrev.2021.102831_bb0130","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3057624","article-title":"Mesenchymal stem cell-based immunomodulation: properties and clinical application","volume":"2018","author":"Wang","year":"2018","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.autrev.2021.102831_bb0135","doi-asserted-by":"crossref","DOI":"10.1089\/neu.2011.2109","article-title":"Transplantation of mesenchymal stem cells promotes an alternative pathway of macrophage activation and functional recovery after spinal cord injury","author":"Nakajima","year":"2012","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.autrev.2021.102831_bb0140","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0145","series-title":"Evidence-Informed Publich Health: Opportunities and Challenges. Abstracts of the 22nd Cochrane Colloquium; 2014 21-26 Sep; Hyderabad, India","article-title":"Rayyan: a systematic reviews web app for exploring and filtering searches for eligible studies for Cochrane Reviews","author":"Elmagarmid","year":"2014"},{"key":"10.1016\/j.autrev.2021.102831_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.autrev.2021.102831_bb0155","first-page":"1","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2021.102831_bb0160","series-title":"JBI Manual for Evidence Synthesis","article-title":"Chapter 7: Systematic reviews of etiology and risk","author":"Moola","year":"2020"},{"key":"10.1016\/j.autrev.2021.102831_bb0165","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/rheumatology\/kel436","article-title":"Local implantation of autologous mononuclear cells from bone marrow and peripheral blood for treatment of ischaemic digits in patients with connective tissue diseases","volume":"46","author":"Kamata","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2021.102831_bb0170","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/s10165-010-0274-x","article-title":"Therapeutic angiogenesis in patients with systemic sclerosis by autologous transplantation of bone-marrow-derived cells","volume":"20","author":"Ishigatsubo","year":"2010","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2021.102831_bb0175","first-page":"854","article-title":"Therapeutic vascular angiogenesis for intractable macroangiopathy-related digital ulcer in patients with systemic sclerosis: A pilot study","volume":"53","author":"Takagi","year":"2014","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.autrev.2021.102831_bb0180","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.3727\/096368914X685636","article-title":"Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis","volume":"24","author":"Del Papa","year":"2015","journal-title":"Cell Transplant"},{"key":"10.1016\/j.autrev.2021.102831_bb0185","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1253\/circj.CJ-18-1044","article-title":"Impact of therapeutic angiogenesis using autologous bone marrow-derived mononuclear cells implantation in critical limb ischemia with scleroderma: \u2014 subanalysis of the long-term clinical outcomes survey \u2014","volume":"83","author":"Shoji","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.autrev.2021.102831_bb0190","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1002\/art.30431","article-title":"Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases","volume":"63","author":"Keyszer","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102831_bb0195","first-page":"1","article-title":"Mesenchymal stem cell therapy for refractory scleroderma: A report of 2 cases","volume":"2016","author":"Wehbe","year":"2016","journal-title":"Stem Cell Investig"},{"key":"10.1016\/j.autrev.2021.102831_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1373-2","article-title":"Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis","volume":"19","author":"Zhang","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2021.102831_bb0205","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/sj.leu.2404996","article-title":"Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L","volume":"22","author":"Christopeit","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.autrev.2021.102831_bb0210","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-153-10-201011160-00007","article-title":"Autologous Mesenchymal stem cells Foster revascularization of ischemic limbs in systemic sclerosis: A case report","volume":"153","author":"Guiducci","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2021.102831_bb0215","doi-asserted-by":"crossref","first-page":"A943","DOI":"10.1136\/annrheumdis-2013-eular.2827","article-title":"Case report of allogeneic unrelated-donor mesenchymal stem cells (MSC) infusion in systemic sclerosis (SSC) AB0505","volume":"72","author":"Chakr","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102831_bb0220","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.semarthrit.2016.12.003","article-title":"Evidence-based management of systemic sclerosis: navigating recommendations and guidelines","volume":"46","author":"Pellar","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102831_bb0225","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jcyt.2012.11.005","article-title":"Mesenchymal stromal cells: misconceptions and evolving concepts","volume":"15","author":"Phinney","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.autrev.2021.102831_bb0230","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3727\/096368915X689622","article-title":"Clinical trials with mesenchymal stem cells: an update","volume":"25","author":"Squillaro","year":"2016","journal-title":"Cell Transplant"},{"key":"10.1016\/j.autrev.2021.102831_bb0235","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.stem.2011.06.008","article-title":"The MSC: An injury drugstore","volume":"9","author":"Caplan","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.autrev.2021.102831_bb0240","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/jcp.25255","article-title":"MSCs: the sentinel and safe-guards of injury","volume":"231","author":"Caplan","year":"2016","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.autrev.2021.102831_bb0245","doi-asserted-by":"crossref","first-page":"11002","DOI":"10.1073\/pnas.0704421104","article-title":"Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury","volume":"104","author":"Ortiz","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2021.102831_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/scrt68","article-title":"Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-\u03b1-induced protein 6","volume":"2","author":"Danchuk","year":"2011","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.autrev.2021.102831_bb0255","first-page":"967","article-title":"Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action","volume":"303","author":"Ionescu","year":"2012","journal-title":"Am J Phys Lung Cell Mol Phys"},{"key":"10.1016\/j.autrev.2021.102831_bb0260","article-title":"Conditioned media from mesenchymal stromal cells restore sodium transport and preserve epithelial permeability in an in vitro model of acute alveolar injury","volume":"306","author":"Goolaerts","year":"2014","journal-title":"Am J Phys Lung Cell Mol Phys"},{"key":"10.1016\/j.autrev.2021.102831_bb0265","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1242\/jcs.02932","article-title":"Mesenchymal stem cells reside in virtually all post-natal organs and tissues","volume":"119","author":"da Silva","year":"2006","journal-title":"J Cell Sci"},{"key":"10.1016\/j.autrev.2021.102831_bb0270","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/art.21212","article-title":"Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source","volume":"52","author":"Sakaguchi","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102831_bb0275","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cardiores.2005.02.006","article-title":"Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia","volume":"66","author":"Iwase","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.autrev.2021.102831_bb0280","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1634\/stemcells.2006-0347","article-title":"Effect of hypoxia on gene expression of bone marrow-derived Mesenchymal stem cells and mononuclear cells","volume":"25","author":"Ohnishi","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.autrev.2021.102831_bb0285","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nm1181","article-title":"Human embryonic stem cells express an immunogenic nonhuman sialic acid","volume":"11","author":"Martin","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2021.102831_bb0290","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3324\/haematol.11446","article-title":"No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients","volume":"92","author":"Sundin","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2021.102831_bb0295","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.autrev.2010.09.008","article-title":"Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis","volume":"10","author":"Galluccio","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0300","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1161\/CIRCRESAHA.108.176826","article-title":"Paracrine mechanisms in adult stem cell signaling and therapy","volume":"103","author":"Gnecchi","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.autrev.2021.102831_bb0305","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.stem.2012.03.007","article-title":"Mesenchymal-stem-cell-induced Immunoregulation involves FAS-ligand-\/FAS-mediated T cell apoptosis","volume":"10","author":"Akiyama","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.autrev.2021.102831_bb0310","first-page":"1","article-title":"Healing potential of mesenchymal stem cells cultured on a collagen-based scaffold for skin regeneration","volume":"16","author":"Shokrgozar","year":"2012","journal-title":"Iran Biomed J"},{"key":"10.1016\/j.autrev.2021.102831_bb0315","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.autrev.2012.10.004","article-title":"Stem cells in autoimmune diseases: implications for pathogenesis and future trends in therapy","volume":"12","author":"Cipriani","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0320","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.autrev.2011.01.005","article-title":"Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases","volume":"10","author":"Ben-Ami","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0325","doi-asserted-by":"crossref","first-page":"102662","DOI":"10.1016\/j.autrev.2020.102662","article-title":"Haematopoietic stem cell transplantation in systemic sclerosis: challenges and perspectives","volume":"19","author":"Di Benedetto","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0330","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.lpm.2016.05.002","article-title":"Stem cell transplantation and mesenchymal cells to treat autoimmune diseases","volume":"45","author":"Tyndall","year":"2016","journal-title":"Presse Med"},{"key":"10.1016\/j.autrev.2021.102831_bb0335","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.autrev.2010.08.011","article-title":"Human cord blood stem cells and the journey to a cure for type 1 diabetes","volume":"10","author":"Zhao","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0340","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3389\/fimmu.2018.02056","article-title":"The use of human Mesenchymal stem cells as therapeutic agents for the in vivo treatment of immune-related diseases: a systematic review","volume":"9","author":"Leyendecker","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2021.102831_bb0345","first-page":"1014","article-title":"Efficacy of mesenchymal stem cells on systemic lupus erythematosus:a meta-analysis","volume":"50","author":"Liu","year":"2018","journal-title":"Beijing Da Xue Xue Bao"},{"key":"10.1016\/j.autrev.2021.102831_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/7061408","article-title":"Prognostic factors for clinical response in systemic lupus Erythematosus patients treated by allogeneic Mesenchymal stem cells","volume":"2019","author":"Wen","year":"2019","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.autrev.2021.102831_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-018-1541-4","article-title":"Serum IFN-\u03b3 levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis","volume":"16","author":"Yang","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.autrev.2021.102831_bb0360","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1089\/scd.2013.0023","article-title":"Human umbilical cord Mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy","volume":"22","author":"Wang","year":"2013","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.autrev.2021.102831_bb0365","first-page":"1","article-title":"The immunomodulatory effects of mesenchymal stromal cell-based therapy in human and animal models of systemic lupus erythematosus","author":"Radmanesh","year":"2020","journal-title":"IUBMB Life"},{"key":"10.1016\/j.autrev.2021.102831_bb0370","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.autrev.2014.10.001","article-title":"Cell-based therapies for systemic lupus erythematosus","volume":"14","author":"Liao","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102831_bb0375","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.transproceed.2012.05.091","article-title":"Quantifying mesenchymal stem cells in the mononuclear cell fraction of bone marrow samples obtained for cell therapy","volume":"45","author":"Alvarez-Viejo","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.autrev.2021.102831_bb0380","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.7150\/ijms.8182","article-title":"Opposite effects of bone marrow-derived cells transplantation in MPTP-rat model of Parkinson\u2019s disease: A comparison study of mononuclear and mesenchymal stem cells","volume":"11","author":"Santos Capitelli","year":"2014","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.autrev.2021.102831_bb0385","first-page":"1","article-title":"Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis","author":"Magalon","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221001038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221001038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:22:26Z","timestamp":1761600146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221001038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":77,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1568997221001038"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102831","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human mesenchymal stem cells for the management of systemic sclerosis. Systematic review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102831"}}